EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypoimmune platforms: from rejection to immune evasion and regulatory implications

Francesco Campo, Maria Irene Bellini, Hanne Scholz, Lorenzo Piemonti, Antonio Citro

Transplant International · 2026

DOI: 10.3389/ti.2026.16845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, 2026. Verfasst von Francesco Campo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Graft Rejection, Immune Evasion, Organ Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The growing gap between organ demand and clinical availability has renewed interest in immune-evasive graft strategies, yet rejection and lifelong immunosuppression remain major barriers to durable success. Advances in genome editing enable immune-evasive cell platforms designed to avoid immune recognition while replacing missing function in allogeneic settings. This review summarizes current strategies for engineering immune-evasive grafts that simultaneously suppress adaptive and innate immune responses. We discuss how coordinated modulation of antigen presentation and immune checkpoint pathways can protect transplanted allogeneic cells and tissues from T, NK, and macrophage-mediated rejection. We also present the emerging concept of integrating hypoimmune engineering with genetically modified porcine donors, where extensive genome editing has reduced, but not eliminated, xenogeneic immune barriers. Combining donor genome modification with immune-evasive graft design represents a promising conceptual advance toward xenograft survival, though whether full elimination of systemic immunosuppression is achievable remains to be established clinically. We further examine how the regulatory landscape for these products is evolving across major jurisdictions, and how differences in approval pathways, manufacturing standards, and long-term surveillance requirements shape the path to clinical translation. Finally, we outline the safety considerations and remaining limitations in immune evasion that must be addressed to enable clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionImmune EvasionOrgan TransplantationHumansAnimalsTransplantation, HeterologousImmunosuppression TherapyGraft SurvivalSwineGene EditingImmunity, InnateAnimals, Genetically Modified

Stichwörter der Autor:innen

genome editinghypoimmuneislet transplantationregulatoryxenotransplantation

Autor:innen und Institutionen

  • Diabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Department of Surgery, Sapienza Università di Roma, Rome, Italy.
  • Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway.
  • Vita-Salute San Raffaele University, Milan, Italy.

Zitieren

APA

Campo, F., Bellini, M. I., Scholz, H., Piemonti, L., & Citro, A. (2026). Hypoimmune platforms: from rejection to immune evasion and regulatory implications. Transplant International. https://doi.org/10.3389/ti.2026.16845

Vancouver

Campo F, Bellini MI, Scholz H, Piemonti L, Citro A. Hypoimmune platforms: from rejection to immune evasion and regulatory implications. Transplant International. 2026. doi:10.3389/ti.2026.16845

BibTeX
@article{Campo2026,
  author = {Campo, Francesco and Bellini, Maria Irene and Scholz, Hanne and Piemonti, Lorenzo and Citro, Antonio},
  title = {Hypoimmune platforms: from rejection to immune evasion and regulatory implications},
  journal = {Transplant International},
  year = {2026},
  doi = {10.3389/ti.2026.16845}
}
Kostenlos starten →